Webinar: Latest data using ctDNA to assess breast cancer recurrence risk and treatment response
This webinar will explore the rapidly evolving role of circulating tumor DNA (ctDNA) in predicting therapy response and disease recurrence in patients with breast cancer, with significant applications for biopharma drug development and clinical practice. Our expert speakers will discuss the latest 2022 data from SABCS, ASCO, and AACR. This will be followed by a panel discussion on the future directions and implications that can be derived from ctDNA data.